BRICKET

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jun 30, 2020 → Oct 24, 2026

Cited window

Oct 23, 2023 → Oct 24, 2026

Retrieved

Oct 28, 2026

Title

Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)

Registry

NCT06578559

Study IDs

BRICKET

Sponsor

Gruppo Oncologico del Nord-Ovest

Collaborators

Merck Sharp & Dohme LLC, Pierre Fabre Laboratories

Design

Phase 2 · Interventional, single group

Status

Completed

Enrollment

16 actual

Start

2024-07-23 actual

Primary completion

2026-05-12 actual

Primary endpoint

Objective Response Rate (ORR)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are X posts and quoted or linked material, not a representative sample of HCP practice. Reposts and duplicate quotations are not additional independent opinions.
• –The search emphasized the trial identifier and names; unnamed references and transcription variants may have been missed. More than 2,000 sources without the trial name were not read, and one potentially relevant discussion was not fully assessed.
• –No separate protocol was listed and no BRICKET results publication was identified. Reported numerical outcomes therefore describe what authors said, not a full appraisal of trial results.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –No substantive safety or tolerability commentary was identified in the reviewed material. This does not establish an absence of toxicity or a favorable benefit–harm balance.
• –Post dates do not establish presentation dates, changes of mind or disagreement across different settings.
• –Cross-study PFS comparisons and biological explanations offered in the posts do not establish comparative efficacy or causal resistance mechanisms.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "BRICKET" (NCT06578559), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "bricket-06578559". If you cannot make requests, read https://www.erudio.com/reports/bricket-nct06578559.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06578559", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06578559 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/bricket-nct06578559.json
curl https://www.erudio.com/reports/bricket-nct06578559.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "bricket-06578559" })